Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease by Glorieux, Griet et al.
toxins
Review
Gut-Derived Metabolites and Their Role in Immune
Dysfunction in Chronic Kidney Disease
Griet Glorieux 1,* , Tessa Gryp 1 and Alessandra Perna 2
1 Nephrology Division, Ghent University Hospital and Ghent University, 9000 Ghent, Belgium;
tessa.gryp@ugent.be
2 First Division of Nephrology, Department of Translational Medical Sciences, School of Medicine,
University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy; alessandra.perna@unicampania.it
* Correspondence: griet.glorieux@ugent.be; Tel.: +32-9-3324511
Received: 11 March 2020; Accepted: 10 April 2020; Published: 11 April 2020


Abstract: Several of the uremic toxins, which are difficult to remove by dialysis, originate from the gut
bacterial metabolism. This opens opportunities for novel targets trying to decrease circulating levels of
these toxins and their pathophysiological effects. The current review focuses on immunomodulatory
effects of these toxins both at their side of origin and in the circulation. In the gut end products of the
bacterial metabolism such as p-cresol, trimethylamine and H2S affect the intestinal barrier structure
and function while in the circulation the related uremic toxins stimulate cells of the immune system.
Both conditions contribute to the pro-inflammatory status of patients with chronic kidney disease
(CKD). Generation and/or absorption of these toxin precursors could be targeted to decrease plasma
levels of their respective uremic toxins and to reduce micro-inflammation in CKD.
Keywords: uremic toxins; gut; chronic kidney disease; immune
Key Contribution: Several uremic metabolites and their precursors exert immunomodulatory effects
both at their side of origin—the colon—and in the circulation. Both intestinal generation and intestinal
transport could be addressed to decrease their levels in the circulation with the aim to reduce
micro-inflammation in chronic kidney disease.
1. Introduction
Under physiological conditions, cells and tissues are maintained in a homeostatic state while
under pathophysiological conditions they experience stress. The latter conditions require adaptation
in which the immune system plays an important role. The characteristics of this adaptive response are
an intermediate between the basal homeostatic state and an inflammatory response, called low-grade
inflammation, switched on in order to restore functionality and homeostasis [1]. Inflammation is
mediated by an interaction of multiple components of the innate and adaptive immune system including
complement factors, leukocytes and cytokines. Chronic kidney disease (CKD) is a state of chronic,
low-grade inflammation which contributes to the accelerated progression of chronic inflammatory
disturbances affecting immune balance with increased levels of innate immunity biomarkers, such
as C-reactive protein (CRP) and interleukin (IL)-6. Causes and consequences of inflammation and
CKD-associated cardiovascular diseases, such as the uremic milieu and infection, have been explored [2].
More recently attention has been paid to the intestine and its microbiota as a potential source of
inflammation due to changes in the gut microbial composition and disruption of the intestinal epithelial
barrier structure and function in CKD. Levels of uremic toxins and their gut-derived precursors
play an important role in the pro-inflammatory response and have been linked to changes in gut
microbiota composition [3]. For a long time, the number of identified colon-derived solutes in humans
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remained limited. Recently, metabolome studies made an important contribution to the identification
of colon-derived solutes by comparing the urinary metabolome from controls to that of patients with
colectomy [4,5]. In addition, the comparison of the plasma metabolome from controls and hemodialysis
patients revealed colon-derived solutes that accumulate when the kidneys fail. Among the identified
colon-derived uremic solutes are the known uremic toxins p-cresyl sulfate (pCS), p-cresyl glucuronide
(pCG), indoxyl sulfate (IxS), indole-3-acetic acid (IAA) and trimethylamine N-oxide (TMAO). Levels
of all five solutes have previously been shown to be increased in patients with CKD [6–9]. Several
biological effects of these compounds have been demonstrated, mainly affecting pathways playing
a role in inflammation, metabolic function, cardiovascular disease and fibrosis [10]. More recently,
alterations in the sulfur metabolism, prominent in CKD, have been linked to changes in the microbiota
composition and function and should be taken into account when evaluating the potential role of
uremic toxins and their precursors in immune response and inflammation at their side of origin [11].
2. The Gut Immune Homeostasis
A large number of microbiota reside in and on our body, with the largest microbial community
located in the gastrointestinal tract [12]. All these microbiota exert metabolic functions, generating
metabolites which directly influence our immune and nervous system and several distal organs via the
circulation [13]. The human immune system plays an essential role in maintaining homeostasis with
resident microbial communities, while resident microbiota per se shape the human immunity [14].
Most knowledge has been gained from studies with germ-free mice and colonized mice revealing the
role of microbial colonization in the formation of lymphoid tissues and subsequent immune system
development [15].
An important role is reserved for the intestinal epithelium which serves as an immunological
guard forming a barrier between the intestinal lumen, containing microbiota and their derivatives and
metabolites, and the internal milieu. The gastrointestinal barrier consists of intestinal epithelial cells
with, at the apical side, tight junction proteins sealing the cellular layer and preventing translocation
from the luminal side towards the blood side. After microbial stimulation, the epithelial cells express
patterns of recognition receptors and produce chemotactic factors affecting both myeloid and lymphoid
cells. Innate lymphoid cells in the submucosa can be stimulated to produce cytokines, while the
dendritic cells in the submucosa often determine whether the response will be pro- or anti-inflammatory.
The composition of the intestinal microbiota and their metabolic activity affects the immune response
in the submucosa mainly via passive and active transcellular transport of solutes regulated at the
apical membrane of the epithelial cells [13,16].
3. Gut Dysbiosis in CKD
The gut microbial composition is altered in CKD patients. This was initially observed in
culture-based approaches observing increased counts of aerobes and decreased counts of anaerobes in
fecal samples [17] and increased counts of aerobes and anaerobes in the small intestines of non-dialyzed
and dialyzed patients with end-stage kidney disease (ESKD) compared to controls [18,19]. Metagenomic
sequencing and qPCR confirmed the altered gut microbial composition in CKD, revealing a difference of
190 microbial operational taxonomic units (OTUs) between ESKD patients and healthy controls [3] and
a decline of the short-chain fatty acid (SCFA)-generating bacteria, Bifidobacterium spp. and Lactobacillus
spp., and an elevation of Enterobacteriaceae and Escherichia coli with progressive stages of CKD [20].
Recently, Wang et al. demonstrated that alterations in the gut microbiome mediate metabolome changes
in patients with ESKD [21]. The alterations in the gut microbial composition, as a potential cause of a
change in the gut biochemical milieu in CKD, is further enhanced by several uremia-related factors,
while the gut microbiota per se also contribute to CKD by generating the uremic toxin precursor
metabolites. This indicates that there is a bidirectional relationship between the gut microbiota and the
kidneys, also known as the gut-kidney axis.
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Gut dysbiosis contributes to the disruption of the intestinal barrier integrity causing translocation of
bacteria and bacterial components which trigger the intestinal immune system. Under these conditions,
intestinal epithelial cells will express pro-inflammatory cytokines, promoting a Th1 and Th17 response
by dendritic cells and macrophages and producing increased levels of commensal-specific IgG by B
cells. Binding of lipopolysaccharide (LPS) to its receptor complex on macrophages further results
in enhanced production of pro-inflammatory cytokines [22]. Circulating endotoxin is a potential
cause of inflammation in CKD [23–25]. A dysregulated immune response and chronic production of
pro-inflammatory cytokines lead to systemic inflammation, which can further accelerate the progression
of CKD and the development of CKD-associated cardiovascular disease.
4. End Metabolites of Intestinal Bacterial Metabolism
The bacterial generation of uremic toxin precursors depends on the availability of carbohydrates
at the level of the colon. In the presence of an excess of carbohydrates, amino nitrogen is mainly
built into the growing bacterial biomass and saccharolytic fermentation prevails, producing SCFAs,
keeping the pH low and suppressing the proteolytic activity [15,26]. However, in CKD, characterized
by a decreased absorption of amino acids and abnormal intestinal motility in the small intestine and
by a prolonged colonic transit [19,27], concentrations of amino acids are higher than expected in the
colon. This induces an upstream expansion of proteolytic species and could lead to an increase in
the metabolization of aromatic amino acids into precursors of uremic toxins, such as p-cresol, indole
and trimethylamine (TMA), and of IAA (Figure 1). In addition, sulfur-containing dietary products
and sulfated mucins are metabolized to form hydrogen sulfide (H2S) [11]. Currently, few reports on
intestinal levels of these metabolites are available [28], while the existing data diverge [29,30]. In the
following paragraphs, the potential biological effects of these metabolites at their side of origin are
described, focusing on cells of the immune system and immune response, as summarized in Table 1.
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Figure 1. End products of the intestinal bacterial metabolism (I, IAA, pC, TMA, H2S) are transported as
such or after detoxification (sulfatation and glucuronidation) towards the liver via the portal vein where
the remaining pC and I are conjugated and TMA is oxygenated. The end products of the bacterial
and human metabolism are taken up into the circulation (IxS, IAA, pCS, pCG, TMAO, H2S) where
some bind to albumin (IxS, IAA, pCS and to a lesser extend pCG). H2S is also generated by different
tissues througho t the body. Finally, these compounds are excreted into the urine. Trp: tryptophan;
Tyr: yrosine; Cys: cysteine; I: indole; IAA: indole-3-acetic acid; pC: p-cresol; TMA: trimethylamine;
TMAO: trimethylamine N-oxide; pCS: p-cresyl sulfate; pCG: p-cresyl glucuronide; IxS: indoxyl sulfate.
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4.1. p-Cresol
p-Cresol (108.14 g/mol) is an end product of the bacterial metabolization of the aromatic amino
acid tyrosine (181.19 g/mol) in the colon. Kawakami et al. reported that fasting in rats enhances the
production of p-cresol due to an increased concentration of endogenous protein in the caecum [31].
At the side of the colonic epithelial cells, in HT29 Glc(−/+) cells, p-cresol has been shown to significantly
increase lactate dehydrogenase leakage and decrease adenosine triphosphate (ATP) content, while in
Caco-2 cell monolayers, p-cresol significantly decreases the transepithelial electrical resistance and
increases the paracellular transport of fluorescent isothiocyanate (FITC)-dextran [32]. In addition,
the genotoxicity of p-cresol was suggested by the induction of DNA damage, affecting cell cycle kinetics
in HT29 and Caco-2 cells [33]. These studies point to the local contribution of p-cresol to the disruption
of the intestinal barrier function, which will indirectly affect the host immune response. Furthermore,
incubation of Lactobacillus casei Shirota-stimulated J774.1 cells, a murine macrophage-like cell line, in the
presence of p-cresol, inhibited IL-12 p40 production in a dose-dependent manner [34]. Previously,
p-cresol was also shown to suppress monocyte and granulocyte respiratory burst activity [35]. These
data suggest that at the side of the intestine, p-cresol could exert deleterious effects on the host defense
system per se.
4.2. Indole and Indole-3-Acetic Acid
Both indole (117.15 g/mol) and indole-3-acetic acid (175.18 g/mol) are metabolites from the bacterial
tryptophan (204.22 g/mol) metabolism. These metabolites are bioactive and can affect the intestinal
barrier function and immune cells via the pregnane X receptor (PXR) and the aryl hydrocarbon receptor
(AhR), both playing a role in the expression of the mucin 2 gene, which is essential for an intact
epithelial barrier [36,37]. Indole functions as a signaling molecule in the gut homeostasis where it
can regulate bacterial motility, biofilm formation, antibiotic resistance, and secretion of virulence
factors affecting host cell invasion by non-indole-producing species, such as Salmonella enterica and
Pseudomonas aeruginosa and even the yeast Candida albicans [38]. Indole has also been recognized as
a beneficial signal molecule in intestinal epithelial cells. It ameliorates intestinal inflammation as
demonstrated by the decreased TNF-α-mediated activation of nuclear factor (NF)-κB, the decreased
expression of the pro-inflammatory chemokine IL-8, and the decreased attachment of pathogenic
E. coli to the human enterocyte cell line, HCT-8 cells, as well as the increased expression of the
anti-inflammatory cytokine IL-10 [39]. Indole also increased the expression of genes involved in
strengthening the mucosal barrier and mucin production, which were consistent with an increase in
the transepithelial resistance of HCT-8 cells [39].
Data on the local effect of IAA in the intestine are limited. Hendrikx et al. reported that restoration
of intestinal levels of IAA protected mice from ethanol-induced steatohepatitis by inducing intestinal
expression of IL-22 and antimicrobial C-type lectin regenerating islet-derived 3 gamma (REG3G),
preventing translocation of bacteria to the liver [40].
In contrast to p-cresol, both indole and IAA exert beneficial effects in the gut by regulating gut
homeostasis and by strengthening the mucosal barrier and mucin production.
4.3. Trimethylamine
The fishy, odorous trimethylamine (59.11 g/mol) is produced from the bacterial metabolization
of dietary products such as phosphatidylcholine and carnitine, found in fish, seafood, eggs, cheese
and red meat. TMA is rapidly absorbed through the gut wall and transported to the liver, where it
is converted into nonodorous TMAO by the enzyme flavin-containing monooxygenase-3. Although
no local intestinal toxic effects could be retrieved from literature, TMA was suggested to affect other
barrier functions such as in the respiratory tract and the skin [41,42].
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4.4. Sulfur Compounds
Among the sulfur compounds present in the gut, H2S is currently one of the most extensively
studied. H2S (34.08 g/mol) is a gas produced by the body, with many biological functions among
which anti-inflammatory and anti-oxidant properties. However, it must be kept in mind that H2S is
also a lethal toxin when present at high concentrations, inhibiting complex IV in the mitochondrial
respiratory electron transfer chain.
The various forms in which H2S is present are: free H2S (gaseous H2S, along with the HS-hydrosulfide
anion, and S2− sulfide anion), the acid-labile sulfur (iron-sulfur clusters and persulfides), and the bound
sulfane sulfur (thiol sulfides, polysulfides, sulfate/sulfite, and bound elemental sulfur). It is produced
both enzymatically and nonenzymatically. Three enzymes are involved: cystathionine β-synthase
(CBS, brain), cystathionine γ-lyase (CSE, vascular tissues, liver, kidney), and 3-mercaptopyruvate
sulfurtransferase (MST, kidney). CBS and CSE belong to the transsulfuration pathway, which is mainly
devoted to (1) the endogenous generation of cysteine, (2) homocysteine detoxification, and (3) H2S
generation (and concomitant lanthionine production). In red blood cells (and other tissues, such as
spleen, heart, lung, muscle, bone marrow) it is likely most often produced nonenzymatically, utilizing
cysteine [43]. H2S can signal through four mechanisms [44]: (1) reduction and/or direct binding of
metalloprotein heme centers; (2) antioxidant action through reactive oxygen species (ROS)/reactive
nitrogen species scavenging; (3) post-translational modification of proteins by addition of a thiol (-SH)
group onto reactive cysteine residues, so-called persulfidation (or S-sulfhydration), and formation
of polysulfides [45,46]; (4) a postulated redox-linked metabolic reprogramming mechanism through
sulfide quinone oxidoreductase in mitochondria [47].
Even considering the difficulties in accurately measuring H2S and the various species in which it
is present [48], its concentration in tissues and blood is usually in the low micromolar range; however,
in the luminal content of the large intestine the total sulfide concentration is about 0.2–2.4 mM [49].
The sources of H2S in the gut are the Sulfate Reducing Bacteria (SRB), gut fermentative bacteria,
and colonic tissues. About 50% of H2S originates from the bacterial metabolization of sulfur-containing
dietary products and sulfated mucins present in the outer mucus layer of the colon [50]. Colon epithelial
cells are adapted to the high environmental H2S exposure; in fact, these cells possess an efficient
mitochondrial H2S oxidation pathway, dedicated to its disposal. Intestinal epithelial cells express
enzyme systems that efficiently degrade sulfide into thiosulfate and sulfate, which are absorbed and
finally excreted in the urine [51,52].
To date, it is not entirely clear if gut H2S is a mediator of a productive mutualistic relationship at
the host–microbial interface or a simple metabolic byproduct of enzymatic reactions, but this is less
likely [42]. It is known that H2S is useful to the local gut bacteria because it increases bacterial resistance
to antibiotics [53], it acts as a protective mechanism against ROS [54], and it provides bacterial resistance
towards elimination by the host immune system [55]. However, the physiologic and regulatory roles
of H2S in a healthy and a diseased gut are still not well defined. Mercaptides, such as H2S, help
to maintain anaerobic conditions in the colonic lumen. There is even evidence that the recycling of
H2S by a “thiosulfate shunt” integrates the enzymatic activities of both the intestinal epithelial cells
and intestinal microbiota. On the other hand, high H2S levels have been shown to inhibit butyrate
oxidation, an important energy source of the colonic epithelial cells [56]. In the end, H2S has beneficial
effects on the local intestinal microbiota, but it could negatively affect the intestinal barrier function
because it has been suggested that H2S plays a potential role in the etiology of bowel disorders such as
inflammatory bowel diseases. In addition, gut-derived H2S is able to exert hypotensive effects [49].
It has been shown in a germ-free mice model that free H2S and bound sulfane sulfur are significantly
reduced in plasma, while acid-labile sulfide levels remain normal [57]. In the same paper, CSE activity
is also lower in several tissues, such as the aorta, the brain, and kidneys. H2S is also significantly
lower in plasma from CKD and hemodialysis patients compared to controls, while the metabolic
related compounds cystathione, homolanthionine and lanthionine are significantly increased [58].
In this respect, lanthionine, a byproduct of the transsulfuration pathway found to be quite high in
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the plasma of CKD patients, is able to exert several toxic effects [59–62]. Lanthionine is also an end
product of bacterial metabolism. Very little is currently known about the levels of these compounds in
the intestinal environment of CKD patients and whether differences in the gut microbiota composition
present in CKD affect H2S levels or its effects.
5. Immunomodulatory Effects of Uremic Toxins from Colonic Origin
5.1. p-Cresyl Sulfate
Detoxification of p-cresol occurs in the mucosa of the colon [63] and in the liver [64], where it is
sulfated into pCS (188.2 g/mol) and a small fraction is glucuronidated into pCG (283.3 g/mol) [65,66].
When entering the circulation these solutes bind to plasma albumin in a reversible manner [67]. pCS
was suggested to cause immune dysfunction and increase the risk of infectious diseases in CKD
patients. Schepers et al. demonstrated for the first time an in vitro biological effect of pCS at uremic
concentrations, revealing an increase in the percentage of leukocytes displaying oxidative burst activity
at baseline and an inhibition of the leukocyte burst activity after stimulation [68]. A synergistic
activating effect was observed when the glucuronide conjugate of p-cresol, pCG, was added [69]. This
was confirmed in an in vivo microscopic rat model where superfusion of the peritoneal membrane
with pCS caused a rapid increase in the number of rolling leukocytes while the combination of both
pCS and pCG caused impaired blood flow and vascular leakage but did not further enhance leukocyte
rolling over pCS alone [70]. Activation of leukocytes per se and increased crosstalk between leukocytes
and the vascular endothelial cells in the presence of pCS may contribute to the pro-inflammatory
condition which is characteristic for CKD patients. In addition, Han and coworkers demonstrated that
pCS promotes plaque growth and instability in ApoE KO mice by enhancing leukocyte-endothelium
interaction [71].
Although the total uremic milieu was shown to suppress monocytic CYP27B1 expression,
an enzyme regulating local production of 1,25-dihydroxyvitamin D3 in monocytes playing a role in the
immunomodulatory effects of vitamin D, no specific contribution of pCS could be demonstrated [72].
Shiba et al. demonstrated that mice fed a tyrosine-rich diet causing pCS accumulation in their blood revealed
a suppressed Th1-type cellular immune response demonstrated by the suppressed production of interferon
(IFN)-gamma and the decreased percentage of IFN-gamma-producing Th1 cells in the presence of pCS [73].
Later on, the same group also demonstrated that pCS suppresses LPS-induced anti-bacterial immune
responses in murine macrophages [74] and decreases peripheral B cells by inhibiting proliferation of
CD43(+) B-cell progenitors in vitro [75]. pCS was shown to induce macrophage activation demonstrated
by increased oxidative burst activity and phagocytosis but interfered in antigen processing, leading
to a failure in adaptive immune response in CKD [76]. Levels of terminally differentiated CD8+ T
cells also positively correlated with the level of pCS pointing to a premature aging phenotype of the
immune system in patients with ESKD [77]. More recently, Borges Bonan and coworkers demonstrated
that a combination of sulfated uremic toxins, among which pCS and IxS contribute to the increasing
proportion of intermediate (CD14++CD16+) pro-inflammatory monocytes in CKD patients [78].
5.2. Indoxyl Sulfate
The intestinally generated indole is further metabolized in the liver to indoxyl sulfate (213.21 g/mol).
Among other uremic toxins, IxS is a ligand of the AhR. The AhR regulates both innate and adaptive
immune responses and is expressed in dendritic cells (DCs). The AhR inhibits the development of
plasmacytoid DCs from bone marrow precursors induced by FMS-like tyrosine kinase-3 ligand (Flt3L),
probably via inhibition of signal transducer and activator of transcription-3 (STAT3) expression [79].
The study by Ghimire et al. suggested an anti-inflammatory and tolerizing effect of IxS on human
DCs [80]. However, in monocytes, the response to IxS through the AhR increases levels of TNF-α and
upon stimulation with TNF-α, human vascular endothelial cells express CX3CL1, a chemokine ligand
of CX3CR1 [81]. In addition, IxS induces monocytic ROS production in an NADPH oxidase-dependent
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manner [82]. The IxS-induced TNF-α production in macrophages is regulated through a mechanism
involving the interaction of AhR, NF-κB, and the suppression of cytokine signaling [83]. IxS also
increases LPS-induced NF-κB nuclear translocation, ROS release and altered calcium concentrations
in J774A.1 macrophages, mainly because of mitochondrial calcium overloading [84]. In RAW 264.7
culture, NF-κB mRNA expression was stimulated by IxS, while nuclear factor erythroid 2-related
factor 2 (Nrf2) was downregulated, triggering inflammation and oxidative stress [85]. Finally, IxS
enhances leukocyte adhesion to the endothelial cells in vitro by the ROS/p38 MAPK pathway and the
ROS/JNK/NF-κB pathway [82,86]. These effects indicate that IxS-mediated immune dysfunction may
cause vascular endothelial cell damage in CKD patients.
5.3. Indole-3-Acetic Acid
In humans, indole acetic-3-acid directly originates from tryptophan metabolism by intestinal
bacteria and from tryptophan in various tissues. The toxic effect of IAA in neutrophils is associated
with cell peroxidase activity [87] and these processes have been involved in the activation of the glucose
and glutamine metabolism [88]. There is a direct correlation between the cytotoxic effect of IAA and
the peroxidase activity of the cells, with neutrophils presenting a higher peroxidase activity than
inflammatory macrophages, whereas in resident macrophages and in lymphocytes this enzyme activity
is very low [89]. IAA leads to marked structural changes and death of cultured neutrophils [87,89],
whereas the toxic effects of IAA on lymphocytes are only observed when exogenous peroxidase is
added to the culture medium or when they are co-cultivated with neutrophils [90]. In addition, IAA
was shown to enhance glucose and glutamine metabolism in neutrophils and thioglycollate-elicited
macrophages. IAA caused a marked increase in oxygen consumption by neutrophils, which was
more pronounced in the presence of glutamine as compared to glucose. The stimulation of oxygen
consumption leads to a reduction in the NADH/NAD+ ratio that activates the flux of substrates through
the Krebs cycle [88]. Subcutaneous IAA administration in rats promotes an increased neutrophil
phagocytic capacity without a pro-oxidant effect [91]. Finally, IAA was shown to damage DNA in
human neutrophils. This genotoxicity negatively correlates with the antioxidant activities, as measured
by the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay [92].
5.4. Trimethylamine N-Oxide
Flavin-containing monooxygenase enzymes encoded by the FMO gene family are involved
in TMAO (75.11 g/mol) production from TMA in the liver, kidney and other tissues [93]. TMAO
up-regulates vascular cell adhesion molecule-1 (VCAM-1) expression, promotes monocyte adherence
and activates protein kinase C (PKC) and p-NF-κB. Interestingly, a PKC inhibitor was able to diminish
the TMAO-stimulated VCAM-1 expression and monocyte adherence. Pharmacological inhibition
revealed that endothelial cell adhesion of leukocytes was necessary for TMAO to induce inflammatory
gene expression [94]. This points to the fact that TMAO promotes an early pathological process
of atherosclerosis [95]. Haghikia et al. suggested that TMAO-related increase of pro-inflammatory
monocytes may add to the elevated cardiovascular risk of patients with increased TMAO levels [96].
5.5. Sulfur Compounds
The effect of H2S on immune function has been investigated in different models, at different
concentrations, with diverged results. H2S is generated at site of inflammation and can influence
the ability of neutrophils to cause tissue injury. The H2S donor, sodium hydrosulfide, was shown
to suppress leukocyte adherence to the vascular endothelium and to reduce leukocyte infiltration.
Suppression of endogenous H2S synthesis through blockade of CSE abolished this anti-inflammatory
effect [97]. Zanardo et al. demonstrated in an intra-vital microscopic rat model that H2S donors
inhibited aspirin-induced leukocyte adherence in mesenteric venules, likely via the activation of
ATP-sensitive K+ channels [98]. Inhibition of endogenous H2S synthesis elicited leukocyte adherence
and leukocyte infiltration was also suppressed by H2S donors and exacerbated by inhibition of
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endogenous H2S synthesis [98]. These results suggest that endogenous H2S is an important mediator
of acute inflammation, acting at the leukocyte-endothelium interface. Key discoveries concerning H2S
were recently reviewed by Szabo [99].
Table 1. (Patho)physiological effects of intestinally generated uremic toxins and their precursors at
their side of origin.
Metabolites Side of Origin (Patho) Physiological Effects Ref.









↓IL-12 p40 production [34]




Regulation of gut homeostasis [38]












Protection against ROS [54]
Protection against immune cells [55]








↑Baseline ROS and ↓ROS after stimulation [68]
↑Rolling [70]
↑Plaque growth and instability [71]
↓IFNγ-producing Th1 cells [73]
↓Anti-bacterial immune response [74]
↓Proliferation of CD43(+) B cell progenitors [75]
↑Macrophage activation
↓Antigen processing [76]







Synergistic to pCS: ↑ROS, impaired blood [69]
flow; vascular leakage [70]
Indoxyl sulfate Liver





↑Leukocyte-endothelial cell adhesion [82,86]
Macrophages:
↑TNF-α [83]
↑NF-κB, ROS, mitochondrial Ca2+ [84]
overload
↓Nrf2 [85]
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Table 1. Cont.





↑Glucose and glutamine metabolism [88]
↑Oxygen consumption [88]

















Regulation of post-translational [100]
modification of NF-κB pathway
Macrophages:
↓Pro-inflammatory cytokine production [44]





↓Cell lysis (glomerular mesangial cells and T-lymphocytes)
LDH: lactate dehydrogenase; ATP: adenosine triphosphate; TE(E)R: transepithelial (electrical) resistance; IL:
interleukin; REG3G: regenerating islet-derived 3 gamma;ND: none described; RBC: red blood cells: ROS: reactive
oxygen species; DCs: dendritic cells; HUVEC: human vascular endothelial cells; VCAM: vascular cell adhesion
molecule: PKC: protein kinase C; COX: cyclooxygenase; NO: nitric oxide.; MPO: myeloperoxidase. ↓: decreased;
↑: increased.
H2S appears to play an important role in the modulation of the immune response by regulating
the post-translational modification of the NF-kB pathway. However, depending on the model and the
concentration used, H2S functions as an activator and an inhibitor towards this pathway [100]. H2S
donors also inhibit macrophage pro-inflammatory cytokine production, as well as cyclooxygenase-2
and nitric oxide production, and decrease macrophage motility. CBS and CSE are regulated by ox-LDLs,
while H2S mitigates ox-LDL-induced cholesterol efflux and foam cell formation [44]. Endogenous
levels of sulfide reversibly inhibit the activity of circulating and endothelium-bound myeloperoxidase
(MPO), suggesting a mediatory role on the oxidant-producing function of the enzyme. Furthermore,
the produced polysulfides, together with MPO-catalyzed sulfide oxidation and the lack of interaction
between MPO and sulfide oxidation products, may envisage a modulatory role of MPO in sulfide
signaling [101]. It has been demonstrated that H2S is able to reduce inflammation in a mononuclear
cell adhesion model by a mechanism related to ADAM17-dependent TNF-α activation [102]. Most
studies on H2S and immune function are related to cellular immunity. However, it has been shown that
antibody cleavage of the disulfide bonds between heavy and light chains and the ensuing sulfhydration
is induced by H2S donors, which also suppresses the alternative complement activation pathway.
H2S-treated antibodies exhibit a marked reduction in antigen-binding ability, and H2S inhibits cell
lysis in glomerular mesangial cells and in human T lymphocytes [103].
Little is known about this topic in CKD and dialysis patients. In uremia, CSE activity is reduced
in blood mononuclear cells from uremic patients on hemodialysis [104]. CSE downregulation could be
due to a uremic toxin, perhaps lanthionine, which is able to reduce H2S production in hepatoma cells.
It is currently unknown if the gut microbiome is able to influence immune function in CKD patients
through sulfur compounds and in particular through H2S.
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6. Conclusions
Several uremic metabolites and their precursors exert immunomodulatory effects both at their
side of origin and especially in the circulation. At the side of the intestine p-cresol, TMA and H2S
can affect the intestinal barrier structure and function and could in this way stimulate cells of the
immune system and contribute to inflammation. In contrast, the bacterial metabolization products of
tryptophan, indole and IAA, seem to be beneficial for the intestinal epithelial cells and the intestinal
mucosa. Aiming at a decreased generation of especially p-cresol, by e.g., changing dietary intake [105]
or by the administration of pre- [106], pro- [107] or synbiotics [108], could contribute to the intactness
of the intestinal barrier function, avoiding pro-inflammatory reactions. However, in view of the local
intestinal beneficial effects of end products of the bacterial tryptophan metabolism, intestinal absorption,
by affecting transporter protein expression and/or function, rather than generation, should be explored
and targeted. Both strategies will contribute to decreased levels of circulating protein-bound uremic
toxins and might reduce micro-inflammation in CKD. To date, little is known about the role of gut
sulfur compounds and H2S, in particular in the context of CKD, where a profound dysregulation of
their metabolism is present.
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